Floatz logo

Botulinum Toxin Type B

Sialorrhea

Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCPhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Sialorrhea cohort.

Asset / SponsorPhaseRating
Glycopyrrolate
Ottawa Hospital Research Institute
Phase 2BB
INCOBOTULINUMTOXINA
Beth Israel Deaconess Medical Center
Phase 2B
Hyoscine
Mersey Care NHS Trust
Phase 1/2CCC
Clozapine
D

Same molecule, other indications

Botulinum Toxin Type B is also rated in:

stroke disorderDormant
BB
Indicative ·
65 / 100
View asset →
brain injuryDormant
B
Indicative ·
61 / 100
View asset →
neoplasmDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →